Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03448575 · ClinicalTrials.gov registry record · NA
Safer Use of Antipsychotics in Youth
A NA study, sponsored by Kaiser Permanente.
- Completed
- Registry status
- NA
- Development phase
- 733
- Enrollment target
NCT03448575: Completed NA study, sponsored by Kaiser Permanente.
NCT03448575 is a NA study that has completed, run by Kaiser Permanente. The registered enrollment target is 733 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03448575, a NA study, has completed, sponsored by Kaiser Permanente.
- COMPLETED
- Registry status
- NA
- Development phase
- 733 participants
- Enrollment target
Study Summary
This study tests the effectiveness of an intervention treatment algorithm vs. usual care control in a practical clinical trial. Control arm providers will receive a standard medication alert in the electronic medical record (EMR) when initiating an antipsychotic prescription for an eligible patient. Intervention arm prescribers will receive an interactive medication alert in the EMR when prescribing for eligible patients and the patient and provider will enter the treatment algorithm (provider - medication alert plus clinical review by a child psychiatrist; patient - offer of personalized behavioral health navigation plus bridging therapy when appropriate). The study aims to recruit 800 eligible patients in 4 health systems.
Primary Outcome
Measured by medication orders placed within the health system
Interventions
- OTHER Control - Provider Medication Alert Only
- OTHER Intervention - Alert + CAP Review AND Enhanced BH Access
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 733 participants |
| Start Date | 2018-03-29 |
| Est. Completion | 2021-12-24 |
| Phase | NA |
What the finished NCT03448575 record still lists
NCT03448575 is an interventional study that assigns participants to a tested intervention. The registered 733 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 2 interventions - of which Control - Provider Medication Alert Only is the first listed.
NCT03448575 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03448575 about?
NCT03448575 is a clinical study titled "Safer Use of Antipsychotics in Youth". This study tests the effectiveness of an intervention treatment algorithm vs. usual care control in a practical clinical trial. Control arm providers will receive a standard medication alert in the electronic medical record (EMR) when initiating an antipsychotic prescription for an eligible patient....
What is the current status of trial NCT03448575?
This trial is currently completed. It is a NA study. The enrollment target is 733 participants. The study started on 2018-03-29. Estimated completion is 2021-12-24.
What interventions are being tested in trial NCT03448575?
The interventions under investigation include: Control - Provider Medication Alert Only (OTHER), Intervention - Alert + CAP Review AND Enhanced BH Access (OTHER).
Who is sponsoring clinical trial NCT03448575?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03448575's enrollment target sits among peer trials
733 145th of 2000 higher than 1,856 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06216301 · 734 participants · Phase 3
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- NCT07231419 · 734 participants · Phase 3
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
- NCT05947851 · 735 participants · Phase 3
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- NCT05999084 · 735 participants
Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI